As revealed in the report of Deutsche Bank, the third quarterly revenue of SINOPHARM (01099.HK)  -0.300 (-0.998%)    Short selling $14.19M; Ratio 17.638%   increased 22.4% to RMB 52 billion. EPS increased 19.2% to RMB 0.26.
Deutsche Bank lifted the target price of Sinopharm from $23.5 to $26, which is equivalent to 20 times of projected P/E ratio. The rating of Sinopharm was maintained as Hold since the current share price has already reflected the positive impacts of SOE reform and operating leverage

Comments

Popular posts from this blog